Clearmind Medicine Inc CMND

$0.79 -0.02 (-1.91%)

Valuation

Market cap
818,000
Revenue TTM
$0
Net income TTM
$-3,860,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.13

Trading

Volume
91,600
Avg volume
545,958
Day's range
$0.78 – $0.82
Shares out
1,019,000
Stochastic %K
6%
Beta
0.81
Analysts
Strong Buy
Price target
—

Price

Company profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound...

Show more

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
973 536 1016
Website
https://www.clearmindmedicine.com
Address
1220 West 6th Avenue, Suite 101, Vancouver, Canada

Latest news

Stocktwits

thatboytrades Sep 28, 3:02 PM
$CMND dilution
0 replies
like11 Sep 24, 3:29 PM
$CMND https://www.investing.com/news/company-news/clearmind-testifies-at-fda-hearing-on-psychedelic-therapies-93CH-4905447
1 replies
like11 Sep 24, 3:27 PM
$SPRC & $CMND https://www.tipranks.com/news/company-announcements/scisparcs-neurothera-expands-u-s-patent-portfolio-for-psychedelic-pea-therapies-with-clearmind
0 replies
Jmiz1986 Sep 23, 8:09 PM
$CMND nice volume rising today. Will this continue into tomorrow ?
0 replies
AConsciousApe Sep 23, 12:52 PM
$CMND undervalued psyche play. Long. Scenario Approx. value/share Cash/liquidation value ~$4.20 Conservative pipeline value $4.50–$6 Moderate pipeline success/value $7–$12 Major clinical breakthrough / partnership $15+
1 replies
focafoca99 Sep 23, 12:17 PM
$CMND published three new patent applications covering LSD, ketamine and ibogaine combos.
0 replies
Stock_Catcher Sep 23, 11:57 AM
$CMND Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
0 replies
LuckyCharm7 Sep 22, 10:01 PM
$CMND when is the next reverse split?
0 replies